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Abstract
Purpose The purpose of this review was to identify potential
candidate predictors of anxiety in women with early-stage
breast cancer (BC) after adjuvant treatments and evaluate
methodological development of existing multivariable models
to inform the future development of a predictive risk stratifi-
cation model (PRSM).
Methods Databases (MEDLINE, Web of Science, CINAHL,
CENTRAL and PsycINFO) were searched from inception to
November 2015. Eligible studies were prospective, recruited
women with stage 0–3 BC, used a validated anxiety outcome
≥3 months post-treatment completion and used multivariable
prediction models. Internationally accepted quality standards
were used to assess predictive risk of bias and strength of
evidence.
Results Seven studies were identified: five were observational
cohorts and two secondary analyses of RCTs. Variability of
measurement and selective reporting precluded meta-analysis.
Twenty-one candidate predictors were identified in total.
Younger age and previous mental health problems were iden-
tified as risk factors in ≥3 studies. Clinical variables (e.g.
treatment, tumour grade) were not identified as predictors in
any studies. No studies adhered to all quality standards.
Conclusions Pre-existing vulnerability to mental health prob-
lems and younger age increased the risk of anxiety after com-
pletion of treatment for BC survivors, but there was no evi-
dence that chemotherapy was a predictor. Multiple predictors
were identified but many lacked reproducibility or were not
measured across studies, and inadequate reporting did not
allow full evaluation of the multivariable models. The use of
quality standards in the development of PRSM within sup-
portive cancer care would improve model quality and perfor-
mance, thereby allowing professionals to better target support
for patients.
Keywords Breast cancer . Anxiety . Predictors . Risk .
Supportive care . Systematic review
Introduction
Increasing numbers of women are living with the conse-
quences of breast cancer and its treatments [1, 2]. In many
countries, cancer services are facing the challenge of meeting
breast cancer survivors’ (BCS) ongoing supportive care needs
[3], with around a third of BCS reporting unmet psychological
supportive care needs, specifically relating to anxiety, worries
about their cancer diagnosis and treatment, and fears of cancer
recurrence [4–6].
Anxiety is one of the most prevalent mental health symp-
toms experienced by BCS [7–9] and is characterised by un-
pleasant feelings of threat or potential harm, often accompa-
nied by disruptive physical (e.g. muscular tension, palpita-
tions, sweating) and cognitive (e.g. restlessness, lack of con-
centration) sensations [10, 11], which may also present along-
side depressive symptoms. Although heightened anxiety is an
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understandable and often adaptive response to an initial cancer
diagnosis, these symptoms may become clinically important
when severity is sustained over time and worry becomes
counterproductive and debilitating, affecting everyday life
[12]. An estimated 20–58% of women with breast cancer
(BC) experience symptoms of anxiety around diagnosis and
during treatments [13, 14], sometimes described as ‘anticipa-
tory anxiety’ and partly due to the inherent threat and uncer-
tainly posed by a BC diagnosis and commencement of treat-
ments [13]. Whilst for most BCS experiencing anxiety these
symptoms will begin to lessen post-treatment, 18–33% will
have symptoms many months and even years after treatment
has ended [12, 15]. This is of particular importance in coun-
tries, such as the UK, where there is a move away from
follow-up care delivered by cancer services for BCS at low
risk of cancer recurrence and late effects (physical and psy-
chological), towards self-care and follow-up in primary care
by general practitioners (GPs), despite the current paucity of
evidence or tools to inform assessment of risk for psycholog-
ical late effects in BCS [16].
Potential predictors of anxiety for BCS after treatment are
unclear and relatively under-researched with little systematic
assessment of the available evidence. Previous reviews ex-
plored efficacy of treatments for anxiety in BCS [17, 18],
prevalence of anxiety across different tumour groups [11,
15] and factors associated with anxiety for women with BC
throughout diagnosis and treatment [14, 19].
A comprehensive review suggested that younger age was
associated with an increased risk of experiencing anxiety dur-
ing treatment and some evidence that anxiety may be higher
amongst women who had undergone more than one type of
cancer treatment, and in particular chemotherapy, but found
no variation for those receiving radiotherapy or by type of
surgery (e.g. mastectomy vs lumpectomy) [14]. However,
the focus of Lim et al.’s review was not to identify potential
predictors of anxiety after treatment, and many of the studies
included were of mixed quality and design (cross-sectional
and longitudinal). This is important because cross-sectional
studies are not designed or able to tell us what characteristics
of the individual, their experience and clinical history influ-
ence future outcomes. Instead, they suggest interesting asso-
ciations [20, 21]. Further, only longitudinal studies which re-
port multivariable analysis, where more than one independent
variables’ (predictors) association with a dependent variable
(outcome) is analysed simultaneously in a statistical model
[22], are able to identify which predictors have the strongest
association with the outcome whilst adjusting for potential
confounding factors [23]. Data from such studies can be used
in the development of predictive risk stratification models
(PRSMs), designed to predict an individual’s risk of hav-
ing—or developing—a specific condition or outcome based
on multiple variables [24, 25]. Being able to stratify according
to risk would be an important step to ensuring that cancer and
supportive services are more effectively and efficiently tai-
lored to identify the future risk of anxiety, alongside any cur-
rent need, in individual BCS and thereby has the potential to
improve the support they receive [16].
The development of PRSM requires identification of po-
tential candidate predictor variables and should be informed
by risk prediction systematic review [26], focused on identi-
fying studies that use longitudinal designs and multivariable
analysis to distinguish the variables most strongly associated
with an outcome [24, 27–29]. Therefore, the aim of this re-
view is to identify candidate predictors of post-treatment anx-
iety for women with early-stage (0–3) breast cancer after com-
pletion of post-surgical/adjuvant treatments. Candidate pre-
dictors were assessed and described using recently developed,
internationally accepted standards for assessing the quality
and strength of evidence in risk prediction research [30, 31].
Findings from this review will inform the development of a
PRSM of anxiety for use in clinical practice.
Methods
Literature search and eligibility criteria
Electronic searches were undertaken in MEDLINE, Web of
Science, CINAHL, CENTRAL and PsycINFO (inception to
November 2015) using a search strategy informed by previ-
ously published strategies [32–34] and included terms for
breast cancer, anxiety and predictive studies (supplementary
material 1). Extensive cross-referencing of selected studies
was undertaken as well as searches of reference lists of previ-
ously published literature reviews [11, 14, 15, 17–19]. The
search strategies from each electronic database were saved
and results downloaded to EndNote X7.5 for electronic bib-
liographic management. The protocol was submitted to the
PROSPERO register [35].
This review included published journal articles of prospec-
tive or retrospective longitudinal studies examining anxiety
after treatment in women with early-stage (0–3) breast cancer
with a baseline measure of predictive factors and at least
3 months’ follow-up after completion of treatment. Eligible
designs included case-control, survey or cohort studies, anal-
ysis of registry data and secondary analysis of prospective
studies (e.g. RCT of cancer treatments). Eligible studies in-
cluded samples of adult (≥18 years) women diagnosed with
stage 0–3 breast cancer who underwent surgical and
(neo)adjuvant treatments. Treatment was defined as including
surgical, radiological therapies and chemotherapy (adjuvant
and neo-adjuvant). Women receiving hormone or biological
therapies were included in the population of interest but not
included in the definition of treatment, as such treatments can
continue for many years after primary and adjuvant treatments
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have ceased and would thereby exclude too many participants
and limit the generalisability and usefulness of the results.
Eligible studies needed to include an outcome of anxiety
symptoms or disorders, measured at least 3 months after active
treatment for non-metastatic BC using a validated screening
tool or diagnostic tool (i.e. consistent with DSM-IVor ICD-10
criteria), including, but not limited to, measures such as the
State-Trait Anxiety Inventory (STAI) [36], Beck Anxiety
Inventory (BAI) [37] and Hospital Anxiety and Depression
Scale-Anxiety (HADS-A) [38], or diagnostic interviews such
as the Structured Clinical Interview (SCID-II) [39]. To ensure
all relevant data were included, if a study reported combined
outcomes, for example, coefficient estimates for mixed anxi-
ety and depression symptoms, they were included in the
review.
The minimum follow-up period for inclusion was at least
3 months after all baseline (predictor) data collection and
treatment (as defined above) was complete. This was chosen
because in the EU, the USA and elsewhere, this usually coin-
cides with the first clinical follow-up appointment when writ-
ten care plans, including continued follow-up in primary, sec-
ondary or shared care, are agreed. Additionally, at this point,
referrals for specialist care and support services can also be
made [40–42]. Full eligibility criteria are available from the
protocol.
In two instances, multiple publications from the same pri-
mary study were found [43, 44]. In line with previous risk
prediction reviews [45], in such cases, the authors compared
the competing studies to identify the most comprehensive/
relevant adjustment and outcome measures, and duration of
follow-up, with the publication meeting the most criteria be-
ing included in the review.
Data extraction
Two reviewers (JH, KC) independently extracted data. A
standardised data extraction form designed specifically for
systematic reviews of prediction models, the CHecklist for
critical Appraisal and data extraction for systematic Reviews
of prediction Modelling Studies (CHARMS) [28], was
adapted for this review. Data extracted included publication
details, sample size, prevalence of outcome (where appropri-
ate), candidate predictors and outcome measurement, includ-
ing length of follow-up. Where available, coefficients, stan-
dard errors, p values, odds or hazard ratios, and confidence
intervals were extracted for the final multivariable model and
for each time point. It was noted if potential candidate predic-
tor data or covariates included in the final model were not
reported.
Candidate predictors were grouped according to three do-
mains: (1) socio-demographic, (2) biomedical and clinical,
and (3) psychosocial and lifestyle behaviours. A similar ap-
proach has been used in other reviews [46]. Whilst it is
acknowledged there is inevitably some overlap between these
three domains, this approach was considered helpful to aid
interpretation of the findings by helping to determine the qual-
ity and depth of evidence in different areas in order to inform
clinical practice, future research and development of concep-
tual models of anxiety amongst BCS. For completeness, data
on time-dependent covariates, that is, a variable that is repeat-
edly measured during the study, were also extracted.
Assessing risk of bias and strength of evidence
The two reviewers (JH, KC) assessed the methodological
quality of all included studies with the validated Quality in
Prognostic Studies (QUIPS) tool developed by the Cochrane
Collaboration Prognostic Methods Group [30]. QUIPS eval-
uates the risk of bias in six domains: study participants, study
attrition, prognostic factor measurement, outcome measure-
ment, study confounding, and statistical analysis and
reporting. Usefully, QUIPS allows for both statistical and nar-
rative sensitivity analysis to be undertaken to assess the impact
of study quality on the study findings. In addition, a modified
version of the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) framework [47], rec-
ommended specifically for risk prediction systematic reviews
[31], was used to assess the strength of evidence for identified
predictors (see supplementary material 2). This framework
identifies six domains that can reduce the quality of evidence
(phase of investigation, study limitations (incorporating
QUIPS risk of bias), inconsistency, indirectness, imprecision,
publication bias) and two that can increase the rating (moder-
ate or large effect size, dose (exposure-response) gradient).
Disagreements were resolved through discussion with third
reviewers (JA or VC).
Data analysis
Heterogeneity in study methodology precluded meta-analysis.
We describe the individual candidate predictors and outcome
measures from the identified studies. Almost all studies re-
ported only adjusted estimates; therefore, these are reported
where available. We also describe the statistical modelling
methods used in order to fully assess the quality of analysis
and strength of evidence.
Results
Identification of studies
In total, 2465 records were initially identified (2456 through
databases and nine from cross-referencing) (Fig. 1). After re-
moving duplicates, 1373 abstracts were initially screened, and
of these, 1180 studies were excluded because the design,
Support Care Cancer
sample and outcome were ineligible, resulting in 193 full-text
articles being obtained and assessed further for eligibility.
Overall, 43 were ineligible due to design or focus, 27 due to
samples, 89 due to outcome measures and 27 due to follow-
up. A final total of seven studies were included and are
described.
Study characteristics
The total sample size was 3238, ranging from 56 to 1801
participants per study (Table 1). The mean age ranged from
48.4 to 56.5 years; however, one study did not provide de-
tailed age data [48] and two specified upper and/or lower age
limits as part of their inclusion criteria [49, 50]. Four samples
were from the UK [48, 49, 51, 52], and one each was from
Sweden [50], Portugal [53] and Hong Kong [54]. Five studies
used observational cohort designs [48–51, 53, 54], and two
undertook secondary analysis of RCT data [51, 52].
Studies used face-to-face interviews [48, 49, 52], self-
completed surveys [50, 51, 53] or a combination of face-to-
face and telephone interviews [54]. The duration and timing of
the follow-up period after treatment completion ranged from
6 months to 6 years (Table 1), with only two studies including
repeated measurements of the outcome [49, 51].
Outcome measures
Five studies used the outcome of anxiety [48, 50, 51, 53, 54],
whereas two presented results for mixed anxiety and depres-
sion [49, 52] (Table 1).
Four studies each used the HADS-A [38], including trans-
lated versions, where appropriate. Two of these studies used
the HADS-A as a continuous outcome measure [53, 54] and
so did not report prevalence (Table 1). Hopwood et al. [51]
reported a borderline anxiety rate of 16% and a probable case
rate of 13% at 5 years, and Saboonchi et al. [50] reported 25%
possible or probable anxiety cases at 12 months after surgery.
Three studies used different clinical outcome measures (the
Structured Clinical Interview [49], Spitzer’s Research
Diagnostic Criteria [52] and the Schedule for Affective
Disorders and Schizophrenia [48]). Burgess et al. reported a
cumulative prevalence of 48% full or borderline cases of anx-
iety and/or depression from diagnosis up until 12months, with
point prevalence reducing to 25% at 2 years, 23% at 3 years,
22% at 4 years and 15% at 5 years [49]. Dean found a point
Fig. 1 Identification of studies
for the systematic review
Support Care Cancer
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prevalence of depression and/or anxiety of 26% at 12 months
[52], and Hill et al. reported 13% with a diagnosis of general-
ised anxiety disorder during the first year after diagnosis [48].
Statistical modelling approaches
Three types of prediction modelling were used. Burgess et al.
[49] used time-to-event modelling with stressful life events as
a time-dependent variable and depression/anxiety as a binary
outcome (Y/N) formedium-term outcome (4months to 2 years
after diagnosis); all other predictors were measured at diagno-
sis. Logistic regression was used to predict longer term out-
come (from 2 to 5 years after diagnosis). All potential predic-
tors that indicated significance at the p ≤ 0.1 level were in-
cluded in the final model.
Four other studies used only logistic models. Saboonchi
et al. [50] used hierarchical logistic regression (possible or
probable anxiety, Y/N); again, the multivariable model only
included predictors that demonstrated bivariate associations
(p ≤ 0.05). Hopwood et al. [51] used proportional odds logistic
regression (for ordinal data; normal, borderline or case anxi-
ety) and did not report any specific selection criteria for inclu-
sion in the model or during modelling. Hill et al. [48] used
Baron and Kenny’s [55] mediation approach whereby selec-
tion for inclusion and duringmodelling is based on hypothesis
and bivariate associations (p ≤ 0.05) (Table 1).
Two studies used linear multiple regression, to model the
HADS-A as a continuous outcome measure at a single spec-
ified time point and predictors measured at completion of
treatment, although selection methods differed. Lam et al.
[54] used the stepwise, backwards method for predictor inclu-
sion during multivariable modelling (confirmed in personal
correspondence, removal criterion was p > 0.05), whereas
Moreira and Canavarro [53] used a hierarchical approach
and only predictors significantly correlated with anxiety
(p ≤ 0.05) were included. Dean [52] reports that predictors
with a bivariate association were included in a stepwise logis-
tic regression (mixed anxiety and depression), but specific
details for this approach are not reported.
Overall, three studies reported all coefficients in the final
multivariable model (i.e. regardless of significance) [48, 49,
51], three studies only reported coefficient data for predictors
found to be significant in the final model [50, 53, 54] and one
study did not report any coefficient data [52] (Table 1).
Risk of bias within and across studies
QUIPS [30] appraisal suggested the studies by Burgess et al.
[49] and Hopwood et al. [51] had the lowest risk of bias
(Table 2). Three studies were assessed to have high risk of
bias in at least one domain [48, 52, 53]. Overall, the studies
had low risk of bias in the domain of outcome measurement,
meaning that they performed well as they used robust andTa
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validated tools which were administered in a consistent way.
Study participation presented low to moderate risk of bias in
all studies. Ratings of bias for study attrition, study
confounding, statistical analysis and reporting, and prognos-
tic factor measurement were more mixed.
Candidate predictors
Twenty-eight individual candidate predictors were evaluated
by the studies, and, overall, 21 were included in a final mul-
tivariable model by at least one study. The remaining seven
were subsequently excluded from final multivariable models
due to non-significant bivariate associations, suggesting an
initial exploratory analysis indicated they were indirect covar-
iates or confounders (Table 1, supplementary material 3). In
addition, five time-dependent covariates were identified
across three studies [49, 51, 54]. Assessment of the strength
of evidence for each candidate predictor is presented accord-
ing to GRADE [31], discussed in the following sections
(Table 3, supplementary material 3).
Socio-demographic characteristics
Five socio-demographic candidate predictors were evaluated:
age, marital status, education level, occupation and sickness
absence. Evidence was graded as moderate for age and low to
very low for the other socio-demographic variables.
Three studies foundolder age reduced the probability of post-
treatment anxiety [49, 51, 54]. A single study found no bivariate
association [50] and so did not include age in the final
Table 2 Quality in Prognostic Studies (QUIPS) risk of bias assessment for included studies
Study source Bias domain
Study 
participation
Study 
attrition
Prognostic 
factor 
measurement
Outcome 
measurement
Study 
confounding
Statistical 
analysis & 
reporting
Burgess et al, 
2005
Hopwood et al, 
2010
Saboonchi et 
al, 2014
Lam et al, 2012
Hill et al, 2011
Moreira et al, 
2010
Dean, 1987
Bias: low risk , moderate risk , high risk . Summary of the domains of bias assessed by QUIPS: Study participation: sample represents the
population of interest on key characteristics. Study attrition: minimal loss to follow-up, not associated with key characteristics. Prognostic factor
measurement: adequately measured. Outcome measurement: adequately measured. Study confounding: important confounders are appropriately
accounted for. Statistical analysis and reporting: appropriate for the design of the study, limiting potential for presentation of invalid or spurious results
Table 3 Strength of evidence for candidate predictors identified across
all included studies
High • Increased risk: previous mental health problems or
treatment; baseline anxiety/depression
Moderate • No association: chemotherapy
• Inconsistent evidence: age (younger age increases risk
or no association)
Low • Increased risk: non-cancer life difficulties, no intimate
confidante
• Reduced risk: higher self-efficacy, higher optimism
• No association: surgery, radiotherapy and hormone
therapies, cancer diagnostic indicators, marital status,
appearance satisfaction, cancer-related shame,
sickness absence
• Inconsistent evidence: severe/adverse life events
(increased risk or no association)
Very low • Reduced risk: ‘housewife’, no breast symptoms
• No association: self-consciousness of appearance,
arm symptoms
• Inconsistent evidence: education (increased risk if less
educated or no association)
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multivariable model, whilst for another it was not reported [53].
Four studies assessed bivariate associations betweenmarital sta-
tus and anxiety outcomes but did not include this in final multi-
variable models [49, 50, 53, 54]. One study reported BCS de-
scribedas ‘housewives’had lower levelsofanxiety (compared to
thosewhowere employed/unemployed/retired) [54]. Saboonchi
et al. [50] considered sickness absence fromwork as a candidate
predictor but found no associationwith 12-month anxiety. Years
in education or level of academic qualification were considered
by three studies. Lam et al. [54] found that thosewith no qualifi-
cations had an increased risk of anxiety; however, the two other
studies suggested no such association [51, 53].
None of the included studies considered other potentially im-
portant socio-demographiccandidatepredictors includingsocio-
economic status, income or measures of deprivation, ethnicity,
religiosity, caring responsibilities or other social determinants.
Biomedical and clinical characteristics
Overall, 11 cancer-related clinical characteristics were ex-
plored and considered as potential candidate predictors.
Several studies assessed treatment characteristics; however,
the strength of evidence was graded low, with the exception
of chemotherapy graded as moderate. Candidate treatment
predictors included type of surgery (e.g. mastectomy vs breast
conservation) [51, 53, 54], axillary surgery [51, 53], endocrine
therapy and chemotherapy [49–51, 53] and radiotherapy [50,
53]. None were found to predict anxiety outcome, and most
studies did not include these in their multivariable analyses.
A single study considered the absence of post-surgery arm
and breast symptoms, with only having no breast symptoms
reducing women’s risk of anxiety at 5-year follow-up [54]. No
studies considered the impact of comorbidities, disability, ex-
perience of neutropenic events during systemic therapies or
the experience of other side effects during treatment, as pos-
sible candidate predictors.
Diagnostic indicators, including axillary node status [51,
53], pathological tumour size [49, 51, 54], tumour grade [49,
51] and histological type [49, 53, 56], were assessed using
bivariate analysis but not included in any multivariable
models due to p values below study thresholds. The strength
of evidence was graded low.
Psychosocial and behavioural lifestyle characteristics
Patients with a previous history of mental health problems
and/or psychiatric treatment were more likely to have anxiety
in two studies [48, 49]. Likewise, anxiety or depression at
baseline was associated with increased risk at follow-up in
three studies [50, 51, 53]. Similarly, anxiety/depression as
time-dependent covariates during the study period (i.e. not just
at baseline but cumulatively measured up to outcome) indicat-
ed increased risk of anxiety at 5-year follow-up in one study
[54]. Due to the consistency and moderate-to-large effect sizes
from multiple studies, the strength of evidence was graded
moderate to high.
Several studies found no association between anxiety and
psychosocial factors, including appearance satisfaction [53],
cancer-related shame [48], self-blame [48] and self-
consciousness about appearance [53]. Specific predictors
found to have an association included lack of an intimate
confidant [49, 50], experiencing severe life difficulties [49]
and low levels of social support [48], all found to increase
the risk, whereas higher optimism and self-efficacy [54] re-
duced the risk of anxiety. However, because these character-
istics were assessed in single studies, the evidence was graded
very low to low. Experiencing a severe adverse life event
(either prior to or soon after cancer diagnosis) was found to
increase the odds of anxiety in one study [50] but showed no
association in another [49], although these studies used het-
erogeneous measures (detailed interview assessment vs. one
item, self-completion) and the evidence was graded as low. No
evidence was found of eligible studies that considered health-
related behaviours or other lifestyle-related factors (e.g.
smoking, diet or physical activity).
Time-dependent covariates
With the exception of anxiety/depression during the study
period, as highlighted earlier, evidence about the remaining
time-dependent covariates was graded low. One study found
that study follow-up time was associated with anxiety, where-
by longer follow-up time reduced the risk of anxiety [51]. Lam
et al. [54] found no bivariate association between recurrence
of breast cancer and anxiety at 5 years. However, they report a
weak dose-response association with post-surgery distress tra-
jectories; those who were more psychologically resilient after
surgery had lower levels of anxiety by 5 years. No studies
considered the role of ongoing side effects or physical symp-
toms from surgery, radiotherapy or systematic therapies as
possible time-dependent covariates.
Discussion
This is the first review to systematically synthesise available lon-
gitudinal evidence from seven studies regarding possible candi-
datepredictorsofanxietyamongstBCSafter treatmenthasended
and they have entered follow-up care. It is notable that the evi-
dence for many candidate predictors is weak, as revealed by this
systematic review using gold-standard tools [30, 31] to evaluate
the quality and robustness of prognostic evidence.
A growing population of BCS worldwide will have long-
term symptoms of anxiety, and healthcare providers currently
lack ways to identify those at greatest risk; thus, new ways to
help distinguish those at greatest risk are required.
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Understanding the predictors of anxiety in BCSmay be useful
to inform and enhance follow-up care through heightened
clinical awareness [24] or the formal use of PRSM alongside
ongoing needs assessments [16].
Results indicate the risk of anxiety is greatest for those with
pre-existing poor mental health and those with heighted anx-
iety around the time of diagnosis/treatment. Although the
measures used varied, previous/baseline mental health predic-
tors showed the strongest association with anxiety across five
studies [48–51, 53]. Likewise, previous research suggests trait
anxiety has a strong association with anxiety symptoms [14],
but this was not assessed in any of the included studies and
warrants further investigation.
In line with a previous review focused on anxiety amongst
women with BC undergoing treatments [14], there was mod-
erately strong evidence that younger BCS had an increased
risk of anxiety [49, 51, 54]. However, this association was not
consistently demonstrated across all studies [50, 53], in line
with the findings from a review of predictors of quality of life
in colorectal survivors [46].
Incontrast toLimetal. [14], the reviewfoundnoevidence that
chemotherapy is a predictor of anxiety in BCS. This lack of
association may be a reflection of the limited sample size and
numberof studies assessing this longitudinally, but analternative
hypothesis is that whilst chemotherapy heightens anxiety in the
period initially prior to and during treatment, this is not sustained
long-term.Alternatively, this lackof association could reflect the
failure of previous research to include more sensitive candidate
predictors such as measures of treatment side effects. Further
longitudinal studies are needed to explore these issues and will
be useful to health professionals seeking to reassure patients
about the long-term impact of treatments.
The studies included in this review incorporated both clin-
ical assessments of anxiety and the HADS [38]. Several stud-
ies aggregated both possible and probable (clinically signifi-
cant) anxiety in their analysis [49–51], but interestingly simi-
lar important predictors emerged regardless of specific out-
come measures used or whether they were treated as continu-
ous, binomial or ordinal.
The results from this review shed light on a number of other
gaps in our current knowledge of predictors of anxiety in BCS.
Classifying types of predictors into different domains revealed
that many potentially important social determinants found to be
importantpredictorsofanxiety inotherchronichealthconditions
or in other cancer samples are yet to be examined longitudinally
in BCS. These include prognostic factors such as income, depri-
vation and debt, caring responsibilities, social support, ethnicity
and fertility [12]. However, a further publication [43] using the
same sample as that of Saboonchi et al. [50] suggests that having
children and financial difficulties are independently associated
with sustainedanxiety andpoor adjustment during treatment and
through to survivorship, and these warrant further investigation
as candidate predictors.
For biomedical and clinical predictors, much of the focus to
date has been on diagnostic markers and treatment indices,
none of which have shown an association with anxiety out-
comes. Only one study included any measurement of the side
effects of treatment and this was limited to breast surgery
symptoms [54], and no longitudinal multivariable evidence
was available for other areas of physical functioning, comor-
bidities or disability.
An interesting observation from the psychosocial and life-
styles domain was the limited overlap in the constructs mea-
sured by individual studies and that few predictive associations
were found. Consequently, where there was an association,
suchasoptimism[54], theevidencewas ratedasweakas itcame
from only one study source. Future research should examine
psychosocial constructs shown to have an association in this
reviewtosee if such findingscanbe replicatedas theymayoffer
important targets for future interventions. Similarly, no evi-
dence was found on health and lifestyle behaviours such as
smoking, exercise and alcohol consumption, which have been
associated with anxiety and quality of life in other chronic
health conditions and some cancer populations [57–60].
Although the statistical methods used in predictive risk re-
search are not new, it is only relatively recently that researchers
havebeguntoexploreandunderstandtheimportanceofadopting
a rigorous methodological approach in developing prediction
models and the need for different approaches to the development
of causationmodels [20, 24, 61]. In developing PRSM, it is now
recognised that candidate predictors may be important even if
they are not considered causal and somay be included if consid-
ered clinically important, evenwhen they do not reach statistical
significance in bivariate analysis [26, 29]. In line with common
practice at the time, most studies reviewed here, excepting
Hopwood et al. [51], did not include potential candidate predic-
tors in themodel if they did not reach a defined level of bivariate
statistical significance. Although all of the studies cited previous
research as informing their study, there was little evidence of
including candidate predictors from previous models, reflecting
the exploratory nature of much of the research to date.
Consequently, many potential candidate predictors have only
been tested in a single study,making comparisons between stud-
ies and their statistical models challenging. No studies reported
thedevelopmentofaPRSMforuse inclinicalpracticeorexternal
model validation eitherwithin the studyor in a subsequent study.
The strength of our findings is enhanced by adherence to sys-
tematic review principles including independent data sources,
systematic identification and retrieval, cross-referencing and a
broad approach to literature searching informed by recommen-
dations. However, several limitations should be noted. Only the
principalauthor(JH)undertooktheinitialscreening,althoughthe
secondreviewer(KC)assessedall theabstracts retrieved.Aswith
all systematic reviews, we cannot be certain that we did not ex-
clude ormiss some important studies; however, we tried tomin-
imise this with assessment of full-text articles for further studies.
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Unlike previous reviews identifying predictors of psychologi-
cal outcomes in cancer patients [14, 46], a key strength of this
review is that it focused on longitudinal data, albeit with varying
length of follow-up (6–72months after completion of treatment);
nevertheless, this did reduce thenumber of available data sources.
However, this was necessary to get an accurate picture of the
current strength of evidence in this area, where associations from
cross-sectional studies are often inaccurately described as predic-
tors, even inarticle titles.This is importantbecausecross-sectional
research, whilst identifying useful preliminary associations, may
be influenced by a form of Neyman’s bias, whereby an apparent
association is spuriousandwhere it isnotpossible todetermine the
direction of influence [21]. Nevertheless, it should be acknowl-
edged that studies with an outcome of combined anxiety and de-
pression were eligible, as we felt it was important to include such
studies as many BCS will experience combined anxiety and de-
pression. Subsequent narrative sensitivity analysis suggested that
the exclusion of these studieswould not have changed the overall
findingofthereview.Afurther limitationoftheevidencegenerally
is the predominance of White-European participants, with only
one study from Asia and none from the Americas, Middle East
or African countries [12]. It is likely that predictors of anxiety in
BCS vary both within and across country by important social,
cultural and healthcare contextual determinants, but as yet such
evidence is unavailable. Additionally, two studies included age
limitations in their recruitment criteria [49, 50], and younger
BCS are likely to have been overrepresented. It will be important
tounpickhowsuchriskprofilesvaryinfutureresearchaswellas to
explore whether candidate predictors vary by location of the pri-
mary cancer and if they vary for other mental health outcomes in
BCS (e.g. depression, psychological distress and fear of
recurrence).
The findings of this review will be used to inform the devel-
opment of a PRSM to individuals at risk of developing, or con-
tinuing to experience, symptoms of anxiety after completion of
treatment for breast cancer. The next stepswill involve statistical
development and validation of the model. A key consideration
for the selection of predictors for inclusion in amodelwill be the
extent to which they can be readily collected as part of routine
clinical practice—importantly, both pre-existing vulnerability to
mental health problems and age should meet this requirement.
Future research will be needed to determine how best to imple-
ment and evaluatewhether healthcare professionals and patients
use PRSM in oncology practice, to ensure more appropriate,
informed assessment of psychosocial need, thus promoting
person-centred care and enhanced service provision [24, 29].
Conclusions
We found evidence that pre-existing vulnerability to mental
health problems and younger age increased the risk of anxiety
after treatment for BCS, but that being treated with
chemotherapy probably does not. We have identified many
gaps and inadequacies in the existing research evidence re-
garding potential predictors of anxiety in BCS after treatment.
This review highlights the lack of validated and well-tested
risk prediction models for use in clinical practice. The use of
quality standards in the development of PRSM within sup-
portive cancer care may improve model quality and perfor-
mance [62], thereby allowing professionals to better target
support for patients. These results will be used to develop
and validate a PRSM with the aim to develop a tool for
healthcare professionals to identify and prioritise interventions
for those at greatest risk of long-term anxiety.
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